Person: İLHAN, MAHMUT MUZAFFER
Now showing 1 - 10 of 45
Publication Metadata onlyRespiation in Acromegalic patients(2012-04-15) AKKOYUNLU, MUHAMMED EMİN; KARAKÖSE, FATMANUR; İLHAN, MAHMUT MUZAFFER; KART, LEVENT; KUTBAY ÖZÇELİK, HATİCE; BAYRAM, MEHMET; SEZER, MURAT; TAŞAN, ERTUĞRUL; AKKOYUNLU, MUHAMMED EMİN; OKYALTIRIK, FATMANUR; İLHAN, MAHMUT MUZAFFER; BAYRAM, MEHMET; TAŞAN, ERTUĞRUL Publication Metadata onlyDoes DRD2 polymorphism influence the clinical characteristics of prolactinoma?(2015-10-01) Ilhan, MAHMUT MUZAFFER; Kahraman, Ozlem Timirci; Turan, Saime; Turgut, SEDA; Karaman, Ozcan; Zeybek, Umit; SHUKUROV, Samir; Yaylim, Ilhan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULObjectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved. Publication Open AccessInvestigation of the Vitamin D Receptor Polymorphisms in Acromegaly Patients(2015-01-01) Ilhan, MAHMUT MUZAFFER; TOPTAS-HEKIMOGLU, Bahar; YAYLIM, Ilhan; Turgut, SEDA; TURAN, Saime; Karaman, Ozcan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULObjective. The genetic structural alterations in the majority of somatotroph adenomas are not clarified and the search for novel candidate genes is still a challenge.We aimed to investigate possible associations between vitamin D receptor (VDR) polymorphisms and acromegaly. Design, Patients, and Methods. 52 acromegaly patients (mean age 45.7 ± 1.9 years) and 83 controls (mean age 43.1 ± 2.6 years) were recruited to the study. VDR polymorphism was determined by polymerase chain reaction-based restriction fragment length polymorphism methods. Results. The distribution of VDR genotypes showed a significant difference in the frequencies of VDR FokI genotypes between patients and controls (𝑃 = 0.034). VDR FokI ff genotype was significantly decreased in acromegaly patients (𝑃 = 0.035) and carriers of FokI Ff genotype had a 1.5-fold increased risk for acromegaly (OR: 1.5, 95% CI: 1.07–2.1; 𝑃 = 0.020). IGF1 levels after treatment were significantly higher in patients carrying the Ff genotype compared to carrying ff genotype (𝑃 = 0.0049). 25(OH)D3 levels were significantly lower in acromegaly patients (𝑃 < 0.001). Conclusions. Our study suggests that VDR FokI genotypes might affect the development of acromegaly and VDR polymorphisms may play a role in the course of acromegaly as a consequence of altering hormonal status. Publication Metadata onlyA novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus(2016-03-01) Ilhan, MAHMUT MUZAFFER; Tiryakioglu, N. O.; KARAMAN, O.; Coskunpinar, E.; YILDIZ, R. S.; TURGUT, SEDA; Tiryakioglu, D.; TOPRAK, HÜSEYİN; TASAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TOPRAK, HÜSEYİN; TAŞAN, ERTUĞRULPurpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI. Publication Metadata onlyTip 1 Diabetes Mellituslu Obez Olguda Bariyatrik Cerrahinin Etkisi(2017-05-03) YASİN, AYŞE İREM; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; MUTLU, EMİNE; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; MUTLU, EMİNE; TAŞAN, ERTUĞRUL Publication Open AccessAn Unusual Case of Cushing’s Syndrome: Coexistence of Functional Pituitary and Adrenal Adenoma(2017-04-01) İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; YASİN ÇETİN, AYŞE İREM; BÜYÜKBAŞLI, NUR; HAMDARD, JAMSHİD; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULA case of adrenocorticotropic hormone (ACTH)-independent Cushing's syndrome, which develops in the course of ACTH-dependent Cushing's disease, is presented in this report. A 47-year-old woman with a past history of surgery and gamma knife radiosurgery because of Cushing's disease was admitted to the endocrinology clinic with weight gain and unregulated blood glucose levels. Hypercortisolemia was still persisting and diagnostic work-up indicated ACTH-independent Cushing's syndrome. Along with the rare possibility of this coexistence, longstanding ACTH hypersecretion can play a role in functional transition of adrenal adenomas. Further studies are needed to clarify the underlying mechanisms. Publication Metadata onlyHipoglisemi sendromunun fotopletismografi ve elektriksel deri iletkenliği sinyalleri üzerindeki etkisi(2014-09-25) OKKESİM, ŞÜKRÜ; ÇELİK, GAMZE; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN Publication Metadata onlyOrucun beyin üzerindeki mikroyapısal etkisinin difüzyon tensör görüntüleme ile değerlendirilmesi(2014-11-16) BAKAN, AYŞE AHSEN; YILDIZ, ŞEYMA; ALKAN, ALPAY; YETİŞ, HÜSEYİN; KURTCAN, SERPİL; İLHAN, MAHMUT MUZAFFER; YILDIZ, ŞEYMA; ALKAN, ALPAY; KURTCAN, SERPİL; İLHAN, MAHMUT MUZAFFER Publication Metadata onlyBariatrik Cerrahi Planlanan Morbid Obez Bireylerde Beden Algisi, Benlik Saygisi Ve Cinselhayat Kalitesinin İncelenmesi(2016-05-15) EKİNCİ, ESRA; BIKMAZ, PERVİN SEVDA; EKİNCİ, İSKENDER; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL Publication Metadata onlyRapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey(2015-01-01T00:00:00Z) Tasan, ERTUĞRUL; HANIMOGLU, Hakan; Turgut, SEDA; Ilhan, MAHMUT MUZAFFER; EVRAN, Sevket; KAYNAR, Mehmet Yasar; TAŞAN, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFERGiant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54x40x40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17x12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.